Pioneering cancer vaccines, DCPrime leverages its DCOne® dendritic cell technology to develop innovative immunotherapies. Their lead candidate, DCP-001, is currently in a Phase 2 study for Acute Myeloid Leukemia (AML), building on promising Phase 1 results. With Orphan Medicinal Product designation in the EU, DCPrime aims to provide effective treatments for hematological cancers, including Multiple Myeloma, and is expanding its platform to target solid tumors and explore synergies with immune modulators.